Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

Resumen:
The influence of sex on immunotherapy response in patients with non-small cell lung cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17ß-estradiol/ER¿/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options. See related article by Anobile et al., p. 3958.